BioMedNewsBreaks Archive - BioMedWire (BMW)

MondayJul 13, 2026 10:15 am

BioMedNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Expands TONMYA Medicare Coverage to 145 Million Lives

Tonix Pharmaceuticals (NASDAQ: TNXP) announced a major managed Medicare agreement for TONMYA(R) (cyclobenzaprine HCl sublingual tablets), adding approximately 9 million Medicare beneficiaries effective Jan. 1, 2027. Combined with previously announced commercial coverage agreements and broad Medicaid availability, the company said TONMYA will have pharmacy coverage reaching approximately 145 million covered lives, or 46% of the U.S. covered market, while discussions with additional commercial and Medicare payers continue. Following the expanded coverage and positive launch metrics, Tonix plans to add 50 sales representatives by mid-third quarter 2026, increasing its commercial sales force to approximately 150 people. The company said it is…

MondayJul 13, 2026 9:30 am

BioMedNewsBreaks – VERAXA Biotech AG (NASDAQ: VRXA) Partners With Ardigen to Advance AI-Driven Cancer Drug Development

VERAXA Biotech (NASDAQ: VRXA) announced a collaboration with AI-driven bioinformatics company Ardigen S.A. to support development of its BiTAC(R) pipeline of T-cell engagers and future antibody-drug conjugates. The partnership will initially focus on developing AI-enabled tools to identify and prioritize synergistic dual-target combinations for VERAXA's BiTAC platform, which is designed to improve tumor targeting while reducing off-target toxicity. VERAXA said integrating artificial intelligence into its research and development strategy could enhance target selection by analyzing large preclinical and clinical datasets, including programs that demonstrated efficacy but failed because of toxicity. The company believes the collaboration will strengthen development of precision…

MondayJul 13, 2026 9:10 am

BioMedNewsBreaks – Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) Completes Analytical Reference Standard Program for ONC010

This article has been disseminated on behalf of Onco-Innovations Limited and may include paid advertising. Onco-Innovations (CBOE CA: ONCO) (OTCQB: ONNVF) announced the successful completion of its analytical reference standard preparation program for A83B4C63, the active pharmaceutical ingredient supporting its lead oncology candidate, ONC010. Completed in collaboration with Dalton Pharma Services, the program established a qualified reference standard to support analytical testing, manufacturing consistency, quality control and future regulatory and clinical activities. The milestone strengthens the company's chemistry, manufacturing and controls ("CMC") framework and follows recent progress in API manufacturing, precursor scale-up, analytical method development and chiral purity testing. Onco-Innovations…

MondayJul 13, 2026 9:00 am

BioMedNewsBreaks – VERAXA Biotech AG (NASDAQ: VRXA) Appoints Carl von Halem Interim Chief Financial Officer

VERAXA Biotech (NASDAQ: VRXA) announced the appointment of Carl von Halem as interim chief financial officer, succeeding Torsten Bürgermeister. The company said it is in the final stages of discussions with a permanent CFO candidate expected to support its next phase of expansion and operational growth, with an update to be provided in due course. Von Halem currently serves as chief financial officer of Xlife Sciences and played a key role in VERAXA's public listing. The company cited his experience in corporate finance, life sciences and technology-driven businesses, as well as his familiarity with VERAXA's operations and strategic development, as…

ThursdayJul 09, 2026 2:19 pm

BioMedNewsBreaks — Why Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Is ‘One to Watch’

Disseminated on behalf of Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) and may include paid advertising. Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) is a biopharmaceutical company focused on developing therapies and biotech solutions targeting neurodegenerative, metabolic and alcohol misuse disorders. QNTM was highlighted in a recent article discussing its advancement of a diversified platform spanning clinical-stage therapeutics, consumer-focused wellness products and strategic investments designed to address areas of significant unmet need. The publication reads, “The company’s strategy combines pharmaceutical research and development with commercialization partnerships and licensing structures intended to support multiple potential revenue streams and long-term growth initiatives. Quantum BioPharma is advancing programs across…

TuesdayJul 07, 2026 12:39 pm

BioMedNewsBreaks — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Reports Positive Safety Review for Phase 1b Sapu003 Trial

Oncotelic Therapeutics (OTCQB: OTLC) and its 45%-owned subsidiary, Sapu Nano (US) LLC, announced that the independent Safety Review Committee has completed its review of the initial three-patient safety cohort in the ongoing Phase 1b SP-03-B101 trial of Sapu003, finding no dose-limiting toxicities and recommending advancement to the next planned dose level. The company also announced plans to expand the study into Europe with additional clinical sites to broaden patient access and support enrollment. Oncotelic said the clinical milestone follows the publication of peer-reviewed research describing the scientific foundation of the Deciparticle(TM) nanomedicine platform and the intravenous everolimus formulation Sapu003. The company said the publication supports the platform's scalable…

TuesdayJul 07, 2026 11:40 am

BioMedNewsBreaks — VolitionRx (NYSE American: VNRX) Study Highlights Prognostic Value of Nu.Q Cancer Assay in Lung Cancer

VolitionRx Limited (NYSE American: VNRX) announced the release of a new clinical study demonstrating the prognostic value of its Nu.Q Cancer Assay in patients newly diagnosed with lung cancer. Conducted with researchers and clinicians at France's Hospices Civils de Lyon, the real-world study found that levels of the assay's H3K27Me3-nucleosome biomarker were associated with cancer stage, overall survival and progression-free survival, while a prognostic model incorporating the biomarker and clinical factors successfully stratified patients into low- and high-risk mortality groups. The paper is currently under peer review. Volition said the findings support the potential use of Nu.Q Cancer to help personalize treatment selection and improve clinical decision-making. The company added that…

MondayJul 06, 2026 12:51 pm

BioMedNewsBreaks — VERAXA Biotech AG (NASDAQ: VRXA) Shareholders Should Watch Novartis Latest $1.5 Billion ADC Acquisition

Novartis has agreed to acquire Myricx Bio for $1.1 billion upfront, with up to $400 million in milestone payments, reinforcing strong pharmaceutical demand for next-generation antibody-drug conjugate ("ADC") technologies. The latest transaction adds to a growing list of multibillion-dollar ADC and T-cell engager ("TCE") deals, highlighting continued strategic investment in differentiated antibody platforms. VERAXA Biotech (NASDAQ: VRXA) operates in one of biotechnology's most active partnering environments, with pharmaceutical companies continuing to commit billions of dollars to differentiated antibody therapeutics. The latest example came this week as Novartis agreed to acquire Myricx Bio for $1.1 billion upfront, plus up to $400 million in milestone payments, to gain access to the company's novel N-myristoyltransferase inhibitor ("NMTi")…

MondayJul 06, 2026 9:20 am

BioMedNewsBreaks – VERAXA Biotech AG (NASDAQ: VRXA) Highlights BiTAC Pipeline Progress, Advances Partnering Strategy

VERAXA Biotech (NASDAQ: VRXA) provided a corporate and pipeline update highlighting progress during the first half of 2026, including continued advancement of its proprietary BiTAC(R) platform and growing interest from potential pharmaceutical partners. The company said its pipeline now includes four BiTAC-based T-cell engager programs targeting solid tumors, two bispecific antibody-drug conjugate ("ADC") programs and two non-BiTAC assets available for partnering. VERAXA said it plans to prioritize investment in its BiTAC portfolio while seeking to monetize selected non-BiTAC programs to help finance future development, with the goal of advancing lead BiTAC-TCE candidate VXA-102 to IND/CTA readiness by early 2028. Company…

ThursdayJul 02, 2026 10:21 am

BioMedNewsBreaks — VERAXA Biotech AG (NASDAQ: VRXA) Initiates Cell Line Development for Lead BiTAC Cancer Therapy Program

VERAXA Biotech (NASDAQ: VRXA) announced the initiation of cell line development for its lead BiTAC(R) T-cell engager ("BiTAC-TCE") program through a collaboration with ATUM, which will apply its Leap-In Transposase(R) technology to generate stable clonal cell lines supporting IND/CTA-enabling activities and future clinical development. The collaboration follows encouraging preclinical data presented at the 2026 American Association for Cancer Research ("AACR") Annual Meeting and is intended to support CMC development, including early process, analytical and formulation development, as well as the production of material for nonclinical studies. VERAXA said its BiTAC-TCE platform is designed to improve tumor selectivity by splitting the T-cell engager into…

News and publishing service for medical and biotechnology related companies

Contact us: 512.354.7000

BioMedNewsBreaks

BioMedNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Expands TONMYA Medicare Coverage to 145 Million Lives

BioMedNewsBreaks – VERAXA Biotech AG (NASDAQ: VRXA) Partners With Ardigen to Advance AI-Driven Cancer Drug Development

BioMedNewsBreaks – Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) Completes Analytical Reference Standard Program for ONC010

BioMedNewsBreaks – VERAXA Biotech AG (NASDAQ: VRXA) Appoints Carl von Halem Interim Chief Financial Officer

BioMedNewsBreaks — Why Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Is ‘One to Watch’

BioMedNewsBreaks — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Reports Positive Safety Review for Phase 1b Sapu003 Trial

BioMedNewsBreaks — VolitionRx (NYSE American: VNRX) Study Highlights Prognostic Value of Nu.Q Cancer Assay in Lung Cancer

BioMedNewsBreaks — VERAXA Biotech AG (NASDAQ: VRXA) Shareholders Should Watch Novartis Latest $1.5 Billion ADC Acquisition

BioMedNewsBreaks – VERAXA Biotech AG (NASDAQ: VRXA) Highlights BiTAC Pipeline Progress, Advances Partnering Strategy

BioMedNewsBreaks — VERAXA Biotech AG (NASDAQ: VRXA) Initiates Cell Line Development for Lead BiTAC Cancer Therapy Program

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search